Histology and grade
Endometrioid, serous, clear cell, carcinosarcoma or other type and tumor grade are clarified.
A gynecologic-oncology review for uterine and endometrial cancers, focused on histology, grade, stage, MMR/MSI or p53 context, prior surgery, radiation, chemotherapy and current pelvic or metastatic disease status.
Uterine cancer is not one uniform diagnosis. Endometrioid, serous, clear cell, carcinosarcoma and sarcoma-type tumors require different review questions. Stage, grade and molecular markers can affect interpretation.
The file should show whether the patient is newly diagnosed, post-surgery, recurrent or metastatic, and whether the main issue is pelvic disease, distant spread or treatment tolerance.
Endometrioid, serous, clear cell, carcinosarcoma or other type and tumor grade are clarified.
MMR/MSI, p53, POLE or other markers are included when available.
Hysterectomy, lymph node assessment, margins and operative findings are documented.
Pelvic, nodal, peritoneal, lung or other metastatic sites are summarized.
Radiation, chemotherapy, immunotherapy, hormonal therapy and response are listed.
Bleeding, pelvic pain, discharge, anemia, urinary/bowel symptoms and performance status are included.
Each item below affects how the file is interpreted, what the physician can answer and whether additional documents are needed before a responsible response.
Aggressive histologies require different interpretation than low-grade endometrioid tumors.
MMR/MSI or p53 context can influence specialist discussion.
Prior surgery and radiation history affect local control questions.
Blood counts, neuropathy, kidney/liver function and fatigue are reviewed.
Most delays happen when the diagnosis is described verbally but the file lacks dates, reports, imaging, pathology or the current specialist recommendation. The documents below are requested before the file is considered ready for review.
The page does not present a hospital visit or travel plan as automatically suitable. Any Cuba-related discussion remains conditional on physician review of the current file.
The file is routed according to histology, stage and prior treatment.
Active bleeding or infection may require local care before international review.
International coordination does not replace specialist suitability decisions.
International coordination should never delay emergency care. If any of the following are present, the patient should be assessed locally first.
No. It explains how the file is organized for review. Suitability, route, timing and safety can only be determined by physicians after reviewing the complete current record.
A summary helps, but it is not enough for most oncology reviews. Pathology, imaging, treatment history, lab results and the latest oncology note are usually needed.
No. Cuba Health Assist coordinates records, communication, translation support and logistics. Medical decisions remain with licensed physicians and the patient’s treating team.
The team will request missing reports before presenting the case as ready. This protects the patient from receiving a weak or unrealistic response.
No. Severe or rapidly worsening symptoms require local emergency or oncology care first. International coordination is not an emergency service.
A coordinator will organize the medical information and guide the next step according to specialist review. The process is designed to be transparent, clinically cautious and written.